Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.42 |
| ▸ | BRS3 | P32247 | 4/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | GCGR | P47871 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19085151 | 0.80 | TP53 (0.45) | KMT2AMEN1CASP6 | |
| SCHEMBL13477423 | 0.79 | CASP6 (0.41) | BRS3KMT2AMEN1CASP6 | |
| SCHEMBL13142352 | 0.79 | BRS3 (0.61) | BRS3TDP1KMT2A | |
| SCHEMBL19085095 | 0.78 | CASP6 (0.41) | CNR1BRS3CNR2KMT2AMEN1 | |
| SCHEMBL13141519 | 0.76 | BRS3 (0.61) | CNR1BRS3P2RX7 | |
| SCHEMBL18346528 | 0.76 | BRS3 (0.61) | CNR1BRS3P2RX7 | |
| SCHEMBL13477522 | 0.72 | GAA (0.41) | BRS3KMT2AMEN1CASP6 | |
| SCHEMBL19085210 | 0.72 | GAA (0.41) | BRS3KMT2AMEN1CASP6 | |
| SCHEMBL13477499 | 0.71 | BRS3 (0.44) | CNR1BRS3CNR2 | |
| SCHEMBL13477534 | 0.71 | MDM2 (0.49) | CNR1BRS3TDP1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10016410-B2 | Tetrahydroisoquinolin-1-one derivative or salt thereof | SELDAR PHARMA INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170189390-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | SELDAR PHARMA INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189390-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | BRS3, BDKRB2, NTSR2 | CNR1 135/4885BRS3 1/4885CNR2 74/4885 |
| US-10016410-B2 | Tetrahydroisoquinolin-1-one derivative or salt thereof | BRS3, BDKRB2, NTSR2 | CNR1 135/4885BRS3 1/4885CNR2 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.